Navigation Links
Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma
Date:12/6/2010

cal activity and survival.

Ron Bentsur, CEO of Keryx, commented, "The data presented at the ASH meeting further demonstrate perifosine's potential beyond the ongoing Phase 3 registration trials in metastatic colorectal cancer and multiple myeloma. It is encouraging to see perifosine's activity as a single agent and in combination with sorafenib in heavily pre-treated, advanced CLL and HL patients, respectively. Moreover, the perifosine-Revlimid® (+ dexamethasone) combination data in multiple myeloma also presented at ASH indicate that the combination is well tolerated demonstrating promising clinical activity."

Perifosine is currently in Phase 3 clinical trials for refractory advanced colorectal cancer and multiple myeloma.  Both of these Phase 3 programs are being conducted under Special Protocol Assessment (SPA) agreements with the FDA, and with Fast Track designations obtained for both indications. Perifosine is also in Phase 1 and 2 clinical development for several other tumor types.

KRX-0401 (perifosine) is in-licensed by Keryx from Aeterna Zentaris Inc. in the United States, Canada and Mexico.

About Keryx Biopharmaceuticals, Inc.Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in Phase 3 clinical
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
2. Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1/2 NP002 Study in the Treatment of Dyskinesias Resulting from Levodopa Therapy for Parkinsons Disease
3. Spherix Announces Post-Hoc Analysis of Phase 3 Trial With D-Tagatose in Diabetes
4. Pfizer Announces Positive Phase 3 Trial Results for Axitinib in Patients With Previously-Treated Metastatic Renal Cell Carcinoma (mRCC)
5. Circassia Achieves Major Reduction in Allergic Reactions to House Dust Mite in Phase II Clinical Study of Novel T-cell Vaccine
6. Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting
7. VIDEO from Merck and Co., Inc available on thenewsmarket.com: In Phase III Study Mercks Investigational CETP Inhibitor Anacetrapib Met Safety and Efficacy Endpoints in Patients with CHD
8. Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients
9. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
10. Reata Pharmaceuticals to Present Data from Pivotal Phase 2b Trial in Type 2 Diabetics With Chronic Kidney Disease
11. Pevions Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... November 2014 Clementia ... gegeben, dass die Europäische Arzneimittel-Agentur (European ... als Orphan-Medizinprodukt an Palovarotene vergeben hat, ... Behandlung von Fibrodysplasia ossificans progressiva (FOP). ... genetische Krankheit, die von schmerzhaften, wiederkehrenden ...
(Date:11/21/2014)... , Nov. 21, 2014 ... European Medicines Agency (EMA) has granted Orphan ... lead product candidate, for the treatment of ... rare, severely disabling genetic disease characterized by ... (flare-ups) and new abnormal bone formation. This ...
(Date:11/21/2014)... Ohio and MELVILLE, N.Y. ... CAH ), one of the world,s largest ... HSIC ), the world,s largest provider of ... health and medical practitioners, today announced that the companies ... one of the most comprehensive service and product offerings ...
Breaking Medicine Technology:Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 2Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 4Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 5
(Date:11/21/2014)... (PRWEB) November 21, 2014 Center for ... workshops titled “Massachusetts Insurance Funding for Autism Workshops” to ... navigate their way through the insurance coverage process. ... Massachusetts law and the most effective ways to access ... Dec. 4 from 6-8:00 p.m. at 331 Montvale Ave., ...
(Date:11/21/2014)... Mo (PRWEB) November 21, 2014 ... the Get With The Guidelines®–Heart Failure Gold-Plus Quality ... outlined by the American Heart Association/American College of ... heart failure patients. , Get With The Guidelines–Heart ... hospital teams provide the most up-to-date, research-based guidelines ...
(Date:11/21/2014)... Columbus, OH (PRWEB) November 21, 2014 ... their contract with the Ohio Chapter, American Academy of ... and provide safe sleep education to parents and caregivers ... and continues through June 30, 2015, provides $75,000 to ... , “The Ohio Children’s Trust Fund is excited to ...
(Date:11/21/2014)... 2014 Big Bud Farms announced today ... of Innovations with Ed Begley Jr., airing via Discovery ... , Big Bud Farms, growers of legal medical marijuana, ... utilization of medical marijuana. , This segment of Innovations ... variety of products for medicating. Viewers will learn about ...
(Date:11/21/2014)... The typical Thanksgiving dinner table is crowded ... gravy and a myriad of mouthwatering desserts. Who would ... year to begin losing weight? Listen closely. With a ... to losing unhealthy, embarrassing and uncomfortable fat while still ... insight to Diet Doc’s calorie loading holiday diet ...
Breaking Medicine News(10 mins):Health News:Center for Autism and Related Disorders to Host Massachusetts Autism Insurance Workshops for Parents 2Health News:Saint Luke’s Mid America Heart Institute Awarded Get With The Guidelines Heart Failure Gold-Plus Quality Achievement Award 2Health News:Saint Luke’s Mid America Heart Institute Awarded Get With The Guidelines Heart Failure Gold-Plus Quality Achievement Award 3Health News:Saint Luke’s Mid America Heart Institute Awarded Get With The Guidelines Heart Failure Gold-Plus Quality Achievement Award 4Health News:Ohio AAP and Ohio Children’s Trust Fund Continue Partnership for Safe Sleep Education Campaign 2Health News:Ohio AAP and Ohio Children’s Trust Fund Continue Partnership for Safe Sleep Education Campaign 3Health News:Big Bud Farms to be Featured in Upcoming Episode of Innovations with Ed Begley Jr. 2Health News:Diet Doc Releases New Calorie Loading Diet Plans - the Perfect Way to Jump Start the Metabolism and Begin Weight Loss During Thanksgiving 2Health News:Diet Doc Releases New Calorie Loading Diet Plans - the Perfect Way to Jump Start the Metabolism and Begin Weight Loss During Thanksgiving 3Health News:Diet Doc Releases New Calorie Loading Diet Plans - the Perfect Way to Jump Start the Metabolism and Begin Weight Loss During Thanksgiving 4
... NEW YORK, February 22 NexGen Biofuels Ltd.,(NASDAQ: ... its symbol to,"NXGN"., The company has changed its ... HCTL to NXGN, to more clearly reflect its new ... and to produce such,fuel through the acquisition of existing ...
... MELVILLE, N.Y., Feb. 22 /PRNewswire-FirstCall/-- Gentiva Health,Services, Inc. ... of,comprehensive home health and related services, announced today ... to 3:55 p.m. ET, Monday, March 3, 2008,at ... in,Orlando, Florida., The event will be available ...
... Calif., Feb. 22 Sutter Health is creating ... care and specialist,physicians committed to providing patients with ... The Sutter Medical Network,will have a presence in ... from Sonoma County to the Central Valley and ...
... Inclinix, Inc., an enrollment,contract research organization (CRO) and provider ... its,executive management team:, -- Steven M. Agnoff, has ... President of Marketing and Product Management. In this ... to the corporate marketing and product ...
... Physicians Coalition,for Injectable Safety has issued a statement ... after reports of serious complications,following treatment with Botox ... Botox(R) injections for cosmetic indications or,who are considering ... recent reports of adverse events, but must put ...
... IT, Sales and Large-Project Management ... Provider,s Partner Channel, BLOOMFIELD HILLS, Mich., Feb. ... (EHR) software and practice,management solutions provider serving healthcare ... has joined,gloStream,s executive management team as chief channel ...
Cached Medicine News:Health News:Gentiva(R) Health Services to Present March 3rd at Raymond James' 29th Annual Institutional Investors Conference in Orlando 2Health News:Gentiva(R) Health Services to Present March 3rd at Raymond James' 29th Annual Institutional Investors Conference in Orlando 3Health News:Sutter Health Launches Northern California Physician Network 2Health News:Sutter Health Launches Northern California Physician Network 3Health News:Inclinix, Inc. Announces Executive Management Team Changes 2Health News:Clarity for Consumers on Botox Complication and Death Reports 2Health News:Clarity for Consumers on Botox Complication and Death Reports 3Health News:Clarity for Consumers on Botox Complication and Death Reports 4Health News:Nationally Recognized Information Technology Veteran and Entrepreneur John Bamberger Joins gloStream, Inc. as Chief Channel Officer 2
Disposable tracheostomy care tray....
Disposable tracheostomy care tray....
... Solution For Your Tracheostomy Care Needs, ... features the latest components for efficient and ... task. Designed by clinicians, these latex-free trays ... patient and caregiver. All of our trays ...
... and alternate care facilities with a ... which offer the finest in nursing ... the guidance of experienced nursing personnel, ... what is required for efficient and ...
Medicine Products: